The effect of vitamin A supplementation on retinoic acid-related orphan receptor γt (RORγt) and interleukin-17 (IL-17) gene expression in Avonex-treated multiple sclerotic patients

J Mol Neurosci. 2013 Nov;51(3):749-53. doi: 10.1007/s12031-013-0058-9. Epub 2013 Jul 19.

Abstract

The aim of this study was to investigate the role of vitamin A on RORγt and IL-17 gene expression in multiple sclerotic patients. Patients in the vitamin A group received 25,000 IU retinyl palmitate per day, while patients in the placebo group took one capsule of placebo per day for 6 months. Gene expression was measured by real-time PCR at the first and end of the study. The results of this study show that vitamin A downregulates IL-17 and RORγt gene expression. No changes in gene expression occurred in the placebo group.

Trial registration: ClinicalTrials.gov NCT01225289.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Down-Regulation
  • Female
  • Humans
  • Interferon beta-1a
  • Interferon-beta / therapeutic use
  • Interleukin-17 / genetics
  • Interleukin-17 / metabolism*
  • Male
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / metabolism*
  • Nuclear Receptor Subfamily 1, Group F, Member 3 / genetics
  • Nuclear Receptor Subfamily 1, Group F, Member 3 / metabolism*
  • Transcription, Genetic / drug effects
  • Vitamin A / administration & dosage
  • Vitamin A / pharmacology*
  • Vitamins / administration & dosage
  • Vitamins / pharmacology*

Substances

  • Interleukin-17
  • Nuclear Receptor Subfamily 1, Group F, Member 3
  • RORC protein, human
  • Vitamins
  • Vitamin A
  • Interferon-beta
  • Interferon beta-1a

Associated data

  • ClinicalTrials.gov/NCT01225289